Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Granada Gold Mine Inc
XTSX:GGM
|
CA |
|
N
|
Nippon Seiro Co Ltd
TSE:5010
|
JP |
|
T
|
Thanapiriya PCL
SET:TNP
|
TH |
|
N
|
Norsyn Crop Technology Co Ltd
SZSE:001231
|
CN |
|
Kingston Financial Group Ltd
HKEX:1031
|
HK |
|
W
|
Warabeya Nichiyo Holdings Co Ltd
TSE:2918
|
JP |
|
D
|
d'Alba Global Co Ltd
KRX:483650
|
KR |
|
A
|
Almondz Global Securities Ltd
NSE:ALMONDZ
|
IN |
|
D
|
Daphne International Holdings Ltd
HKEX:210
|
CN |
|
T
|
TASCO Bhd
KLSE:TASCO
|
MY |
|
S
|
Swarna Securities Ltd
BSE:531003
|
IN |
|
B-SOFT Co Ltd
SZSE:300451
|
CN |
|
Dah Sing Banking Group Ltd
HKEX:2356
|
HK |
|
Mirait One Corp
F:5FO
|
JP |
|
ABOUT YOU Holding SE
XETRA:YOU
|
DE |
|
Superkrane Mitra Utama Tbk PT
IDX:SKRN
|
ID |
|
YPF SA
NYSE:YPF
|
AR |
|
H
|
Harvia Oyj
OMXH:HARVIA
|
FI |
Novan Inc
Total Assets
Novan Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Total Assets
$90.3m
|
CAGR 3-Years
46%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Assets
$199.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Assets
$90B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Assets
$208.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Assets
$136.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Assets
$112.5B
|
CAGR 3-Years
31%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Total Assets?
Total Assets
90.3m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Total Assets amounts to 90.3m USD.
What is Novan Inc's Total Assets growth rate?
Total Assets CAGR 5Y
34%
Over the last year, the Total Assets growth was 31%. The average annual Total Assets growth rates for Novan Inc have been 46% over the past three years , 34% over the past five years .
